Health Care · Pharmaceutical Preparations

AGIO AGIOS PHARMACEUTICALS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1439222113 filings
Russell 2000

AGIO at a glance

AGIOS PHARMACEUTICALS, INC. (AGIO, SEC CIK 1439222) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), AGIOS PHARMACEUTICALS, INC. (AGIO) reported revenue of $54.0 million (up 48.0% from FY2024) and a net loss of $412.8 million. Diluted EPS was -$7.12.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding AGIOS PHARMACEUTICALS, INC. (AGIO) shares worth $993.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Gheuens Sarah on October 26, 2026 of 7,866 shares at $37.69 per share.
  • In the last 90 days, AGIO insiders reported 0 open-market purchases ($0) and 3 open-market sales ($371K) on Form 4, a net sale of $371K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$54.0M
+48.0% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$371K
13F holders
27 funds
$993.7M · +1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Commercial-stage biopharma focused on rare hematology diseases via PK activator small molecules
  • New regulatory approvals for mitapivat: FDA approval of AQVESME™ for thalassemia anemia (Dec 2025), Saudi Arabia approval for PYRUKYND®, EMA positive opinion pending final decision early 2026
  • Strategic shift: Divested oncology business in 2021, monetized vorasidenib milestone and royalty rights for total $1.1B cash inflow by 2024
  • R&D investment milestone: $10M milestone payment to Alnylam in 2025 under license for siRNA candidate AG-236 in polycythemia vera
  • Noteworthy metric: Completed phase 3 SCD trial with mitapivat, 40.6% hemoglobin response vs 2.9% placebo, launched U.S. commercial thalassemia product in Jan 2026

Risk Factors

  • Regulatory risk: FDA REMS requirements for AQVESME™ due to boxed warning on hepatocellular injury risk
  • Macroeconomic risk: geopolitical events like war impacting patient enrollment and clinical trial site operations internationally
  • Supply chain risk: reliance on third-party CROs and contractors with limited control over compliance and timelines
  • Market disruption risk: competition for patient enrollment from other companies’ clinical trials in same indications
  • Financial risk: $130M potential milestone and royalty payments under license agreement with Alnylam for siRNA candidate targeting TMPRSS6

Management Discussion & Analysis

  • Revenue from PYRUKYND® and AQVESME™ product sales began in 2022 and 2026 respectively; milestone income $200M in 2024 from Vorasidenib FDA approval
  • Net income $673.7M in 2024 driven by $1.09B total gain from Vorasidenib royalty rights sale and milestone payment, net loss $412.8M in 2025, net loss $352.1M in 2023
  • Best segment: Oncology contingent payments, $889.1M gain in 2024 from contingent payments sale; Worst segment: ongoing R&D and commercialization expenses driving net losses in 2025
  • Cash inflows include $905M from sale of Vorasidenib Royalty Rights in 2024; R&D expenses include $17.5M upfront license payment plus $10M milestone payment to Alnylam in 2025
  • Future outlook: FDA pre-sNDA meeting Q1 2026 for mitapivat in sickle cell disease; EU approval expected early 2026; continued investment in clinical trials and commercialization expansion

AI summary of the AGIO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New legal risk: Annora’s April 17, 2026 Paragraph IV challenge to PYRUKYND® patents triggered infringement litigation filed May 26, 2026
  • Regulatory risk: FDA requested mitapivat SCD REMS information, extending the PDUFA goal date to February 1, 2027
  • Operational risk: AQVESME® commercialization depends on REMS compliance, with FDA enforcement possible for failures by Agios or its service provider
  • Competitive risk: Generic PYRUKYND® entry could follow patent litigation, although FDA approval is stayed until at least August 17, 2029
  • Financial risk: Nine-month 2026 net loss reached $264.9 million, with accumulated deficit of $826.6 million as of September 30, 2026

Management Discussion & Analysis

  • Q3 revenue $55.4M, up $42.5M YoY from $12.9M, driven by AQVESME® sales
  • Net loss $65.0M vs $103.4M YoY, with operating expenses $132.5M vs $129.7M
  • Best-performing line: U.S. product revenue $48.7M vs $12.3M, driven principally by AQVESME®
  • Cash, equivalents and marketable securities $907.0M; operating cash outflow $235.5M for nine months
  • PDUFA date for mitapivat in SCD extended to February 1, 2027; potential headwinds include increased commercialization costs and further capital needs

AI summary of the AGIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Agios Pharmaceuticals’ quarter ended September 30, 2026
  • Results and business highlights are detailed in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 product revenue $55.4M, more than four times $12.9M, signaling rapid commercial ramp for mitapivat
  • U.S. revenue $48.7M and ex-U.S. revenue $6.6M, supported by AQVESME thalassemia launch and European expansion
Filed Jul 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 mitapivat revenue $44.7M, up from $12.5M, indicating accelerating commercial adoption
  • AQVESME launch generated 442 cumulative U.S. thalassemia prescriptions by June 30, 2026

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, with business highlights issued July 30, 2026
  • Detailed financial results and operating updates contained in Exhibit 99.1 press release
Filed Jun 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stockholders approved 2,000,000 additional shares under Agios’s 2023 Stock Incentive Plan
  • Incentive stock-option capacity also increased by 2,000,000 shares

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Rahul Ballal, Brian Goff and Cynthia Smith elected as Class I directors through 2029
  • Cynthia Smith faced 14,592,704 withheld votes, indicating comparatively weaker shareholder support

AI summaries of AGIO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AGIO

Don't miss the next AGIO filing

  • Alerts as it files. A push when AGIO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AGIO, by share count.
  • Ask anything. An AI agent that reads every AGIO filing and answers with sources.

AGIO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gheuens SarahSellOct 26, 2026$37.69
Gheuens SarahMOct 26, 2026-
Gheuens SarahMOct 26, 2026$25.01
Gheuens SarahMOct 22, 2026$25.01
Gheuens SarahMOct 22, 2026-
Gheuens SarahSellOct 22, 2026$37.52
Gheuens SarahSellOct 21, 2026$37.53
Gheuens SarahMOct 21, 2026$25.01

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$36.5M$54.0M
Operating Income--$425.7M-$472.1M
Net Income-$352.1M$673.7M-$412.8M
Op. Margin--1166.5%-873.9%
Net Margin-1845.9%-764.0%
Balance Sheet
Total Assets-$1.7B$1.3B
Equity$811.0M$1.5B$1.2B
ROE-43.4%43.7%-34.6%
Per Share
EPS$-6.33$11.64$-7.12
Cash Flow
Operating CF--$389.8M-$373.0M
CapEx$999K$1.7M$4.3M

Source: XBRL data in AGIOS PHARMACEUTICALS, INC. (AGIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AGIO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AGIO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$993.7M
Q2 202626$973.1M
Q1 202627$770.1M
Q4 202524$644.9M
Q3 202525$808.4M
Q2 202525$744.6M
Q1 202522$452.2M
Q4 202419$411.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 195 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AGIO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 28, 2026--
4Oct 23, 2026--
4Aug 6, 2026--
10-QJul 30, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 10, 2026--
SC 13GJul 2, 2026-
4Jul 2, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--

Related Health Care companies

All Health Care →

AGIO SEC filings: frequently asked questions

Are AGIO insiders buying or selling?

In the last 90 days, AGIOS PHARMACEUTICALS, INC. (AGIO) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $371,112 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AGIO stock?

As of September 30, 2026, the largest AGIOS PHARMACEUTICALS, INC. (AGIO) holders among the 13F filers tracked by SignalX were BlackRock ($207.1 million), D.E. Shaw & Co ($129.3 million), Morgan Stanley ($114.3 million), State Street Corp ($108.5 million), Vanguard Portfolio Management LLC ($94.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AGIO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), AGIOS PHARMACEUTICALS, INC. (AGIO) reported revenue of $54.0 million (up 48.0% from FY2024) and a net loss of $412.8 million. Diluted EPS was -$7.12. The figures come from the XBRL data in the 10-K.

What are the main risks in AGIO's latest 10-K?

In the 10-K filed February 12, 2026, AGIOS PHARMACEUTICALS, INC. (AGIO) flagged: Regulatory risk: FDA REMS requirements for AQVESME™ due to boxed warning on hepatocellular injury risk. Macroeconomic risk: geopolitical events like war impacting patient enrollment and clinical trial site operations internationally. (AI summary of the Risk Factors section.)

What did AGIO report in its latest 8-K?

AGIOS PHARMACEUTICALS, INC. (AGIO) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Agios Pharmaceuticals’ quarter ended September 30, 2026.

What are the latest AGIO SEC filings?

AGIOS PHARMACEUTICALS, INC. (AGIO) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 28, 2026.

What is AGIO's SEC CIK number?

AGIOS PHARMACEUTICALS, INC. (AGIO)'s SEC Central Index Key (CIK) is 1439222. EDGAR lists every AGIO filing under that number.

Ask anything about AGIO

The research agent reads AGIO's filings, financials, insider trades and 13F holders, then answers with sources.